Research
Hormonal
Tirzepatide, a GLP-1/GIP receptor co-agonist, was approved by the FDA for the treatment of T2DM and provides superior HbA1c reductions.
Healthcare providers can utilize tirzepatide as a more effective treatment option for T2DM.
StrongSupportsmedium confidence
The GLP-1/GIP receptor co-agonist, tirzepatide, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of T2DM, outperforming basal insulin or selective GLP-1RAs by providing superior HbA1c reductions.
Why this rating
The claim is based on regulatory approval and comparative efficacy data.
Source
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Xianxian Huang et al. · Journal of Endocrinology · 2024
DOI 10.1530/joe-23-0404
reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →